<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url><loc>https://peptide.global/story/wegovy-mash-guidance-korean-liver-society</loc><news:news><news:publication><news:name>Peptide Global</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T18:15:00.000Z</news:publication_date><news:title>Wegovy MASH guidance from Korean liver doctors arrives before local approval</news:title></news:news></url>
  <url><loc>https://peptide.global/story/efsubaglutide-alfa-arcera-licence</loc><news:news><news:publication><news:name>Peptide Global</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T17:33:00.000Z</news:publication_date><news:title>Efsubaglutide alfa licence takes a Chinese GLP 1 drug to Arcera markets in four regions</news:title></news:news></url>
  <url><loc>https://peptide.global/story/unapproved-peptides-new-zealand-rise</loc><news:news><news:publication><news:name>Peptide Global</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T17:12:00.000Z</news:publication_date><news:title>Unapproved peptides in New Zealand rise as customs parcels more than double and needle demand jumps</news:title></news:news></url>
  <url><loc>https://peptide.global/story/wegovy-pill-australia-launch</loc><news:news><news:publication><news:name>Peptide Global</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T16:32:00.000Z</news:publication_date><news:title>Wegovy pill Australia launch puts a peptide tablet on private scripts ahead of Foundayo</news:title></news:news></url>
  <url><loc>https://peptide.global/story/who-type-1-diabetes-guidelines-insulin</loc><news:news><news:publication><news:name>Peptide Global</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T16:04:00.000Z</news:publication_date><news:title>Type 1 diabetes guidelines from WHO back human insulin as countries chase 2030 access goals</news:title></news:news></url>
  <url><loc>https://peptide.global/story/once-monthly-semaglutide-korea-trials</loc><news:news><news:publication><news:name>Peptide Global</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T13:47:00.000Z</news:publication_date><news:title>Once monthly semaglutide trials from Daewoong and Peptron win Korean approval on the same day</news:title></news:news></url>
  <url><loc>https://peptide.global/story/korea-obesity-drug-imports-oversight</loc><news:news><news:publication><news:name>Peptide Global</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T13:19:00.000Z</news:publication_date><news:title>Korean doctors want obesity drug imports tracked from customs to clinic and prices cut at home</news:title></news:news></url>
  <url><loc>https://peptide.global/story/mounjaro-cardiovascular-indication-health-canada</loc><news:news><news:publication><news:name>Peptide Global</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T12:53:00.000Z</news:publication_date><news:title>Mounjaro cardiovascular indication approved by Health Canada after a head to head trial with Trulicity</news:title></news:news></url>
  <url><loc>https://peptide.global/story/kyinsu-indication-eu-widen</loc><news:news><news:publication><news:name>Peptide Global</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T12:27:00.000Z</news:publication_date><news:title>Kyinsu indication in the EU set to widen as the label waits on a Commission decision</news:title></news:news></url>
</urlset>